Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Alessandro Leonetti, Sugandhi Sharma, Roberta Minari, Paola Perego, Elisa Giovannetti, Marcello Tiseo

Research output: Contribution to journalReview article

Abstract

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Despite the documented efficacy of osimertinib in first- and second-line settings, patients inevitably develop resistance, with no further clear-cut therapeutic options to date other than chemotherapy and locally ablative therapy for selected individuals. On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms. Furthermore, data from repeat plasma genotyping analyses have highlighted differences in the frequency and preponderance of resistance mechanisms when osimertinib is administered in a front-line versus second-line setting, underlying the discrepancies in selection pressure and clonal evolution. This review summarises the molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS–mitogen-activated protein kinase (MAPK) or RAS–phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation, as well as discussing the current evidence regarding potential new approaches to counteract osimertinib resistance.

Original languageEnglish
Pages (from-to)725-737
Number of pages13
JournalBritish Journal of Cancer
Volume121
Issue number9
DOIs
Publication statusPublished - Oct 29 2019

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Clonal Evolution
Mutation
osimertinib
Phosphatidylinositol 3-Kinases
Oncogenes
Protein-Tyrosine Kinases
Protein Kinases
Phosphotransferases
Pressure
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. / Leonetti, Alessandro; Sharma, Sugandhi; Minari, Roberta; Perego, Paola; Giovannetti, Elisa; Tiseo, Marcello.

In: British Journal of Cancer, Vol. 121, No. 9, 29.10.2019, p. 725-737.

Research output: Contribution to journalReview article

Leonetti, Alessandro ; Sharma, Sugandhi ; Minari, Roberta ; Perego, Paola ; Giovannetti, Elisa ; Tiseo, Marcello. / Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. In: British Journal of Cancer. 2019 ; Vol. 121, No. 9. pp. 725-737.
@article{cdd45688e99d4b30bbffbc0b329c2e8d,
title = "Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer",
abstract = "Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Despite the documented efficacy of osimertinib in first- and second-line settings, patients inevitably develop resistance, with no further clear-cut therapeutic options to date other than chemotherapy and locally ablative therapy for selected individuals. On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms. Furthermore, data from repeat plasma genotyping analyses have highlighted differences in the frequency and preponderance of resistance mechanisms when osimertinib is administered in a front-line versus second-line setting, underlying the discrepancies in selection pressure and clonal evolution. This review summarises the molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS–mitogen-activated protein kinase (MAPK) or RAS–phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation, as well as discussing the current evidence regarding potential new approaches to counteract osimertinib resistance.",
author = "Alessandro Leonetti and Sugandhi Sharma and Roberta Minari and Paola Perego and Elisa Giovannetti and Marcello Tiseo",
year = "2019",
month = "10",
day = "29",
doi = "10.1038/s41416-019-0573-8",
language = "English",
volume = "121",
pages = "725--737",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

AU - Leonetti, Alessandro

AU - Sharma, Sugandhi

AU - Minari, Roberta

AU - Perego, Paola

AU - Giovannetti, Elisa

AU - Tiseo, Marcello

PY - 2019/10/29

Y1 - 2019/10/29

N2 - Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Despite the documented efficacy of osimertinib in first- and second-line settings, patients inevitably develop resistance, with no further clear-cut therapeutic options to date other than chemotherapy and locally ablative therapy for selected individuals. On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms. Furthermore, data from repeat plasma genotyping analyses have highlighted differences in the frequency and preponderance of resistance mechanisms when osimertinib is administered in a front-line versus second-line setting, underlying the discrepancies in selection pressure and clonal evolution. This review summarises the molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS–mitogen-activated protein kinase (MAPK) or RAS–phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation, as well as discussing the current evidence regarding potential new approaches to counteract osimertinib resistance.

AB - Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Despite the documented efficacy of osimertinib in first- and second-line settings, patients inevitably develop resistance, with no further clear-cut therapeutic options to date other than chemotherapy and locally ablative therapy for selected individuals. On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms. Furthermore, data from repeat plasma genotyping analyses have highlighted differences in the frequency and preponderance of resistance mechanisms when osimertinib is administered in a front-line versus second-line setting, underlying the discrepancies in selection pressure and clonal evolution. This review summarises the molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS–mitogen-activated protein kinase (MAPK) or RAS–phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation, as well as discussing the current evidence regarding potential new approaches to counteract osimertinib resistance.

UR - http://www.scopus.com/inward/record.url?scp=85074293851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074293851&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0573-8

DO - 10.1038/s41416-019-0573-8

M3 - Review article

C2 - 31564718

AN - SCOPUS:85074293851

VL - 121

SP - 725

EP - 737

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -